If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> DERMATOLOGY<br /> EMJ Dermatol. 2018 Suppl 2 • europeanmedical-journal.com<br /> INSIDE<br /> The Changing Landscape<br /> of Psoriasis: New Horizons<br /> for Oral Therapies<br /> Psoriasis: From Gene<br /> to Clinic<br /> The Changing Landscape of Psoriasis:<br /> New Horizons for Oral Therapies<br /> This symposium took place on 14th September 2017,<br /> as part of the 26th European Academy of Dermatology and<br /> Venerology (EADV) Congress held in Geneva, Switzerland<br /> Chairperson: Wolf-Henning Boehncke1<br /> Speakers: Wolf-Henning Boehncke,1 Peter Weisenseel2<br /> 1. Faculty of Medicine, University of Geneva, Geneva, Switzerland<br /> 2. Dermatologikum Hamburg, Hamburg, Germany<br /> Disclosure: Prof Boehncke has received honoraria as a speaker and advisor for AbbVie, Almirall<br /> S.A., Amgen, Biogen Idec, Celgene, Leo, Lilly, MSD, Novartis, Pfiz<a title="EMJ Dermatol. 2018 Suppl 2 page 1" href="http://viewer.zmags.com/publication/9008a6aa?page=1"> DERMATOLOGY EMJ Dermatol. 2018 Suppl 2 • european</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 2" href="http://viewer.zmags.com/publication/9008a6aa?page=2"> The Changing Landscape of Psoriasis: New Hor</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 3" href="http://viewer.zmags.com/publication/9008a6aa?page=3"> While efficacy and safety are important</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 4" href="http://viewer.zmags.com/publication/9008a6aa?page=4"> 50 45 Proportion of patients with PASI 75 (%) 4</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 5" href="http://viewer.zmags.com/publication/9008a6aa?page=5"> to achieve optimal efficacy and tolerability prio</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 6" href="http://viewer.zmags.com/publication/9008a6aa?page=6"> maintenance at the lower dose until adaptation to</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 7" href="http://viewer.zmags.com/publication/9008a6aa?page=7"> Altered leukocytes Altered lymphocytes Eosinoph</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 8" href="http://viewer.zmags.com/publication/9008a6aa?page=8"> Dr Weisenseel noted that careful selection o</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 9" href="http://viewer.zmags.com/publication/9008a6aa?page=9"> 13. Mrowietz U, Reich K. Dear-Doctor- L</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 10" href="http://viewer.zmags.com/publication/9008a6aa?page=10"> Psoriasis: From Gene to Clinic This symposium to</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 11" href="http://viewer.zmags.com/publication/9008a6aa?page=11"> in psoriasis and other diseases has been a</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 12" href="http://viewer.zmags.com/publication/9008a6aa?page=12"> Several other antibodies targeting the Th17 </a> <a title="EMJ Dermatol. 2018 Suppl 2 page 13" href="http://viewer.zmags.com/publication/9008a6aa?page=13"> mechanisms, such as the proinflammatory cy</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 14" href="http://viewer.zmags.com/publication/9008a6aa?page=14"> One preclinical study in particular has shown tha</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 15" href="http://viewer.zmags.com/publication/9008a6aa?page=15"> area, with further developments expected.</a> <a title="EMJ Dermatol. 2018 Suppl 2 page 16" href="http://viewer.zmags.com/publication/9008a6aa?page=16"> 39. Abraham C, Cho J. Interleukin-23/ Th</a>